Business Description
Genelux Corp
NAICS : 541714
SIC : 2834
ISIN : US36870H1032
Description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.24 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.49 | |||||
| Beneish M-Score | -296.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.6 | |||||
| 3-Year EPS without NRI Growth Rate | -25.6 | |||||
| 3-Year FCF Growth Rate | -41.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.23 | |||||
| 9-Day RSI | 54.39 | |||||
| 14-Day RSI | 52.69 | |||||
| 6-1 Month Momentum % | -66.25 | |||||
| 12-1 Month Momentum % | -91.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.01 | |||||
| Quick Ratio | 6.01 | |||||
| Cash Ratio | 5.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.2 | |||||
| Shareholder Yield % | -25.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -341437.5 | |||||
| Net Margin % | -331725 | |||||
| FCF Margin % | -277787.5 | |||||
| ROE % | -111.97 | |||||
| ROA % | -81.31 | |||||
| ROIC % | -475.51 | |||||
| 3-Year ROIIC % | 238.78 | |||||
| ROC (Joel Greenblatt) % | -841.16 | |||||
| ROCE % | -104.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 324.34 | |||||
| PB Ratio | 2.08 | |||||
| Price-to-Tangible-Book | 2.08 | |||||
| EV-to-EBIT | -1.95 | |||||
| EV-to-Forward-EBIT | -1.48 | |||||
| EV-to-EBITDA | -2.02 | |||||
| EV-to-Revenue | 6475.13 | |||||
| EV-to-Forward-Revenue | 5439.12 | |||||
| EV-to-FCF | -1.96 | |||||
| Price-to-Net-Current-Asset-Value | 2.87 | |||||
| Price-to-Net-Cash | 2.99 | |||||
| Earnings Yield (Greenblatt) % | -51.28 | |||||
| FCF Yield % | -28.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genelux Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.008 | ||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 0 | ||
| Volatility % | 74.72 | ||
| 14-Day RSI | 52.69 | ||
| 14-Day ATR ($) | 0.23428 | ||
| 20-Day SMA ($) | 2.404 | ||
| 12-1 Month Momentum % | -91.14 | ||
| 52-Week Range ($) | 1.6 - 26.07 | ||
| Shares Outstanding (Mil) | 34.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genelux Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genelux Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genelux Corp Frequently Asked Questions
What is Genelux Corp(GNLX)'s stock price today?
The current price of GNLX is $2.27. The 52 week high of GNLX is $26.07 and 52 week low is $1.60.
When is next earnings date of Genelux Corp(GNLX)?
The next earnings date of Genelux Corp(GNLX) is 2024-11-14 Est..
Does Genelux Corp(GNLX) pay dividends? If so, how much?
Genelux Corp(GNLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers